Ablynx

Ablynx is a listed Belgian biotech focused on the discovery and development of innovative products for serious diseases, including inflammation, haematology and oncology

  • Ablynx placed 4,908,332 new shares to fund ongoing and future clinical trials
  • Kempen & Co acted as Joint Bookrunner and generated significant demand resulting in the upsizing of the deal from an initial €30m at launch to a total of €41.7m
Disclaimer Kempen & Co Privacy statement Asset Management Privacy statement Merchant Banking Statement under the UK Modern Slavery Act Cookie Settings
Kempen & Co NV is part of Van Lanschot Kempen Van Lanschot